Switch theme
Sign up to access all valuation multiples
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
2017
n/a
LTM Revenue $53.4M
LTM EBITDA -$98.1M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mabwell has a last 12-month revenue of $53.4M and a last 12-month EBITDA of -$98.1M.
In the most recent fiscal year, Mabwell achieved revenue of $27.5M and an EBITDA of -$116M.
Mabwell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mabwell valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $17.6M | $27.5M | XXX | XXX | XXX |
| Gross Profit | $3.8M | $17.4M | XXX | XXX | XXX |
| Gross Margin | 22% | 63% | XXX | XXX | XXX |
| EBITDA | -$129M | -$116M | XXX | XXX | XXX |
| EBITDA Margin | -733% | -423% | XXX | XXX | XXX |
| Net Profit | -$132M | -$145M | XXX | XXX | XXX |
| Net Margin | -747% | -527% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mabwell's stock price is CNY 22 (or $3).
Mabwell has current market cap of CNY 8.8B (or $1.2B), and EV of CNY 9.8B (or $1.3B).
See Mabwell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.2B | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mabwell has market cap of $1.2B and EV of $1.3B.
Mabwell's trades at 25.3x LTM EV/Revenue multiple, and -13.8x LTM EBITDA.
Analysts estimate Mabwell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mabwell and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 49.0x | XXX | XXX | XXX |
| EV/EBITDA | -11.6x | XXX | XXX | XXX |
| P/E | -8.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMabwell's NTM/LTM revenue growth is 169%
Mabwell's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Mabwell's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mabwell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mabwell and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -423% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -254% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 39% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 392% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 584% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mabwell acquired XXX companies to date.
Last acquisition by Mabwell was XXXXXXXX, XXXXX XXXXX XXXXXX . Mabwell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mabwell founded? | Mabwell was founded in 2017. |
| Where is Mabwell headquartered? | Mabwell is headquartered in China. |
| Is Mabwell publicy listed? | Yes, Mabwell is a public company listed on SHG. |
| What is the stock symbol of Mabwell? | Mabwell trades under 688062 ticker. |
| When did Mabwell go public? | Mabwell went public in 2022. |
| Who are competitors of Mabwell? | Similar companies to Mabwell include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mabwell? | Mabwell's current market cap is $1.2B |
| What is the current revenue of Mabwell? | Mabwell's last 12-month revenue is $53.4M. |
| What is the current EBITDA of Mabwell? | Mabwell's last 12-month EBITDA is -$98.1M. |
| What is the current EV/Revenue multiple of Mabwell? | Current revenue multiple of Mabwell is 25.3x. |
| What is the current EV/EBITDA multiple of Mabwell? | Current EBITDA multiple of Mabwell is -13.8x. |
| What is the current revenue growth of Mabwell? | Mabwell revenue growth between 2023 and 2024 was 56%. |
| Is Mabwell profitable? | Yes, Mabwell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
